Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Frontiers in Oncology

Megumi Aoki¹  Shigeto Matsushita¹  Ryota Tanaka²  Yasuhiro Fujisawa²  Hiroo Hata³  Keisuke Imafuku³  Takeru Funakoshi⁴  Atsushi Otsuka⁵  Hiroyuki Irie⁵  Yumi Nonomura⁵  Naoko Wada⁶  Hiroshi Uchi⁶  Setsuya Aiba⁷  Taku Fujimura⁷  Yumi Kambayashi⁷  Akira Hashimoto⁷  Kayo Tanita⁷  Takanori Hidaka⁷  Yota Sato⁷  Koji Yoshino⁸  Hisako Okuhira⁹  Yuki Yamamoto⁹ 

[1] Department of Dermato-Oncology, Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan;Department of Dermatology, Faculty of University of Tsukuba, Tsukuba, Japan;Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;Department of Dermatology, Keio University School of Medicine, Tokyo, Japan;Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan;Department of Dermatology, Kyushu University Graduate School of Medicine, Fukuoka, Japan;Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan;Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan;Department of Dermatology, Wakayama Medical University, Wakayama, Japan;

关键词: sCD163;    TAMs;    melanoma;    nivolumab;    prediction of efficacy;   

DOI  :  10.3389/fonc.2018.00530

来源: DOAJ

【 摘 要 】

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

【 授权许可】

Unknown